Global Polymeric Biomaterials Industry is Poised to Experience Significant Growth in the Coming Years

Global Polymeric Biomaterials

Biopolymeric materials have emerged as suitable alternatives to conventional materials in several biomedical applications due to their flexibility in design, processing and property optimization. These materials are extensively used across dental, cardiovascular, orthopedic and wound healing applications owing to their biocompatibility and ability to mimic natural tissues. For instance, polymers such as poly(lactic-co-glycolic acid) or PLGA are effectively used in controlled release applications and tissue engineering due to their tunable degradation properties.

 

Several clinical researches are also ongoing to explore the potential of biopolymeric materials for developing artificial organs, scaffolds and drug delivery carriers. The widespread adoption of Polymeric Biomaterials  -based products and rapid commercialization of new technologies are expected to fuel the industry growth.

Rising Prevalence of Chronic Diseases Globally

The increase in elderly population and changing lifestyle patterns have led to a rise in the incidence of chronic diseases worldwide in recent years. As per the estimates of World Health Organization, cardiovascular diseases, cancer, chronic respiratory diseases and diabetes accounted for around 73% of all deaths globally in 2020. The growing disease burden along with increasing healthcare expenditure is encouraging medical technology companies to focus on developing innovative treatment options and biomaterial-based solutions. This is rapidly driving the demand for advanced biopolymeric materials in clinical applications. In addition, favorable government policies and availability of funding for R&D activities pertaining to biomedical technologies will further support industry expansion over the coming decade.

Strong Foothold of North America in the Global Marketplace

North America, at present, captures over 35% share of the global biopolymeric materials market owing to presence of major players, availability of advanced healthcare infrastructure and strong government funding for clinical research. The U.S. stands as a major contributor due to well-established medical device industry and availability of reimbursement policies propelling the adoption of high-end technologies. Major players based in the region are actively engaged in R&D activities to develop novel biomaterial formulations for tissue engineering, coronary stents, orthopedic implants and wound healing applications. The in-depth understanding of material science along with continuous focus on innovation is helping North American companies to sustain their leading position in the market. However, Asia Pacific region is also viewed as an emerging hotspot with high growth prospects attributable to rising healthcare spending, growing middle-class population and improving economic conditions.

Favorable Demographics and Healthcare Infrastructure Driving Growth in Asia Pacific

The Asia Pacific polymeric biomaterials industry is estimated to witness considerable expansion over the coming years propelled by strong economic growth, rising per capita incomes and favorable demographics across populous countries like India and China. Expanding patient pool due to increasing incidence of chronic and lifestyle diseases complemented by growing healthcare spending provide a positive outlook for market players. Moreover, improving healthcare infrastructure in line with the government initiatives to strengthen medical technology sectors offers significant opportunities. Several leading global medical device companies have set up their manufacturing bases in the region to leverage low-cost skilled labor and cater to the local as well as international markets. Thus, the combination of supportive macrofactors and rapidly increasing accessibility of advanced care is fueling the demand for innovative biomaterial solutions in Asia Pacific.

Significant Adoption of Bioresorbable Polymers

Bioresorbable polymers have emerged as viable alternatives to conventional implant materials owing to their temporary mechanical support and controlled degradation properties as per the tissue healing process. Polymers like polyglycolic acid (PGA), polylactic acid (PLA), polycaprolactone (PCL) are extensively used in fabricating bioresorbable stents, grafts, sutures and bone fixation devices. These temporary scaffolds eliminate the need for secondary surgical intervention for implant removal as they get metabolized post completion of healing. Several bioresorbable polymer-based products have received regulatory approvals and are commercially available for coronary intervention procedures and orthopedic trauma applications. Furthermore, research efforts are underway to develop advanced resorbable polymeric formulations for cardiovascular scaffolds, tissue engineering scaffolds and drug delivery matrices. As a whole, bioresorbable polymers are expected to contribute significantly to the revenues of global biopolymeric materials industry over the next decade.

Stringent Regulations and Quality Standards

The medical devices and biomaterials industry operates under stringent regulations and high quality compliance standards set by regional regulatory agencies such as U.S. FDA, EU's MDR, China's NMPA and Japan's PAL to ensure patient safety. Manufacturers have to comply with multiple regulatory guidelines pertaining to product design, developmental process, manufacturing practices, sterilization, packaging and clinical evaluation. Regulatory compliance involves high cost implications requiring extensive documentation and facility infrastructure audits. In addition, lack of uniform global regulatory framework poses trade barriers and delays new product commercialization plans of companies. Nevertheless, regulatory approvals provide credibility and market access opening up lucrative opportunities over the long-term. Companies are investing heavily in developing robust quality management systems and strengthening regulatory capabilities to have an adaptable approach in the evolving regulatory space.

Promising Growth Prospects with Continuous Technological Advancements

Polymeric biomaterials industry is poised to witness healthy growth riding on the back of rising chronic disease burden, aging population demographics, favorable government support for healthcare sector, expanding clinical trials and commercialization of new technologies. Further, ongoing material development activities directed towards mimicking natural tissues, controlled drug delivery, tissue replacement and regeneration would augment the product portfolio and drive revenues. Positive clinical outcomes of early-stage product pipelines pertaining to bone, cartilage and skin regeneration hold significant promise. Continuous focus on R&D, strengthening of distribution network and strategic collaborations between industry and academia will further aid the industry progress. Thus, with substantial opportunities for technological innovation and expansion across diverse end-use applications, global Biopolymeric materials industry is well-placed to carve an impressive growth trajectory over

 

Get more insights on This Topic- Global Polymeric Biomaterials